These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 33280832)

  • 1. PI3Kδ and mTOR dual inhibitors: Design, synthesis and anticancer evaluation of 3-substituted aminomethylquinoline analogues.
    Yevale D; Teraiya N; Lalwani T; Dalasaniya M; Kapadiya K; Ameta RK; Sangani CB; Duan YT
    Bioorg Chem; 2024 Jun; 147():107323. PubMed ID: 38583254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-Arylquinolines as novel anticancer agents with dual EGFR/FAK kinase inhibitory activity: synthesis, biological evaluation, and molecular modelling insights.
    Elbadawi MM; Eldehna WM; Abd El-Hafeez AA; Somaa WR; Albohy A; Al-Rashood ST; Agama KK; Elkaeed EB; Ghosh P; Pommier Y; Abe M
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):349-372. PubMed ID: 34923887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, Synthesis and Molecular Docking Studies of Pyrazoline Derivatives as PI3K Inhibitors.
    Kumar R; Kumar A; Kumar A; Singh AK; Kumar P
    Comb Chem High Throughput Screen; 2024; 27(2):256-272. PubMed ID: 37143279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, Synthesis, and Biological Evaluation of Quinoline (Quinolinone) Derivatives as NADPH Oxidase (NOX) Inhibitors.
    Zhang L; Yang X; Yi R; Wu S; Li Q; Hu G; Chen Z
    Chem Biol Drug Des; 2024 Aug; 104(2):e14610. PubMed ID: 39160642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study on the effects of rapamycin and the mTORC1/2 dual inhibitor OSI-027 on the metabolism of colon cancer cells based on UPLC-MS/MS metabolomics.
    Fan K; Wang Y; Bian J; Sun Y; Dou J; Pan J; Yu Y
    Invest New Drugs; 2024 Aug; 42(4):418-427. PubMed ID: 38916794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacophore-based virtual screening for the identification of the novel Src inhibitor SJG-136 against lung cancer cell growth and motility.
    Weng CW; Li JH; Tsai JY; Lin SH; Chang GC; Liu CC; Chen JJ
    Am J Cancer Res; 2020; 10(6):1668-1690. PubMed ID: 32642283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting EGFR/PI3K/AKT/mTOR signaling in lung and colon cancers: synthesis, antitumor evaluation of new 1,2,4-oxdiazoles tethered 1,2,3-triazoles.
    Ayoup MS; Shawki I; Abdel-Hamid H; Ghareeb DA; Masoud A; Harras MF; El-Atawy M; Alharbi NS; Ismail MMF
    RSC Adv; 2024 May; 14(24):16713-16726. PubMed ID: 38784419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Towards specific inhibition of mTORC2.
    Murray ER; Cameron AJM
    Aging (Albany NY); 2017 Dec; 9(12):2461-2462. PubMed ID: 29232655
    [No Abstract]   [Full Text] [Related]  

  • 9. Inhibition of cancer cells by Quinoline-Based compounds: A review with mechanistic insights.
    Saxena A; Majee S; Ray D; Saha B
    Bioorg Med Chem; 2024 Apr; 103():117681. PubMed ID: 38492541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel 4-trifluoromethyl-2-anilinoquinoline derivatives as potential anti-cancer agents targeting SGK1.
    Xu G; Li L; Lv M; Li C; Yu J; Zeng X; Meng X; Yu G; Liu K; Cheng S; Luo H; Xu B
    Mol Divers; 2024 Aug; ():. PubMed ID: 39117890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular docking of potential inhibitors with the mTOR protein.
    Fathima JS; Selvaraj J; Sivabalan V; Rekha UV; Ponnulakshmi R; Vishnupriya V; Kullappan M; Sreekandan RN; Mohan SK; Vijayalakshmi P
    Bioinformation; 2021; 17(1):212-217. PubMed ID: 34393439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Quinoline Compounds as KRAS Inhibitors for Treating Cancer.
    Sabnis RW
    ACS Med Chem Lett; 2023 Jun; 14(6):707-708. PubMed ID: 37312857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Suppression of miR-199a-3p by Promoter Methylation Contributes to Papillary Thyroid Carcinoma Aggressiveness by Targeting RAP2a and DNMT3a.
    Wu F; Lin X; Shan SK; Li F; Xu F; Zhong JY; Guo B; Zheng MH; Wang Y; Mo ZH; Yuan LQ
    Front Cell Dev Biol; 2020; 8():594528. PubMed ID: 33365310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the Prognostic Values of the CXCR1-7 in Clear Cell Renal Cell Carcinoma (ccRCC) Microenvironment.
    Wu Z; Zhang Y; Chen X; Tan W; He L; Peng L
    Front Mol Biosci; 2020; 7():601206. PubMed ID: 33324682
    [No Abstract]   [Full Text] [Related]  

  • 15. Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient.
    Boutros A; Schiavi C; Cecchi F; Spagnolo F; Guadagno A; Tanda ET; Giusti F; Murdaca G; Queirolo P
    Front Immunol; 2020; 11():579523. PubMed ID: 33312171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of basic leucine zipper transcription factor E4BP4 in cancer: a review and update.
    Wang L; Li P; Zhang X; Gu Z; Pan X; Wu Y; Li H
    Mol Biol Rep; 2024 Jan; 51(1):91. PubMed ID: 38193973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Marine-Derived
    Widada J; Damayanti E; Mustofa M; Dinoto A; Febriansah R; Hertiani T
    Microorganisms; 2023 Jul; 11(8):. PubMed ID: 37630491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-silico identification of small molecule benzofuran-1,2,3-triazole hybrids as potential inhibitors targeting EGFR in lung cancer via ligand-based pharmacophore modeling and molecular docking studies.
    Kumar S; Ali I; Abbas F; Khan N; Gupta MK; Garg M; Kumar S; Kumar D
    In Silico Pharmacol; 2023; 11(1):20. PubMed ID: 37575679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and development of Tetrahydro-Quinoline derivatives as dual mTOR-C1/C2 inhibitors for the treatment of lung cancer.
    Chaube UJ; Rawal R; Jha AB; Variya B; Bhatt HG
    Bioorg Chem; 2021 Jan; 106():104501. PubMed ID: 33280832
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.